Alex Delaney-gesing

Alcon, Inc. has purchased Neurotech Pharmaceuticals, Inc., developer of the first and only FDA-approved treatment for Macular Telangiectasia Type 2 (MacTel). Big news … let's start with what we know about this deal. Alcon shared two details surrounding th... See more

Stuart Therapeutics submitted an investigational new drug (IND) application amendment to the FDA for ST-100 (vezocolmitide) ophthalmic solution, its lead candidate, for corneal wound healing. First, let's get some background on this asset. ST-100's active... See more

Eyepoint, Inc. released topline results from the phase 3 LUCIA study evaluating DURAVYU (EYP-1901; vorolanib intravitreal insert) for the treatment of wet age-related macular degeneration (AMD). Hold up — didn't the company just report phase 3 data for we... See more

The FDA has approved Alcon's BRYTLY Redness Reliever Eye Drops, expanding the global company's over-the-counter (OTC) portfolio of redness-relief products. And take note: This marks the first nonprescription drop in the U.S. with apraclonidine to receive ... See more

A new month—and season—translates to changes … and we certainly have some updates in the eyecare leadership space to report. The biggest shake up: Bausch + Lomb Corporation has named a new interim CEO. Meanwhile, a few other companies have made their own ... See more